A recent study from the prestigious Journal of American Medicine (JAMA) found that 70% of CBD products were mislabeled or misbranded. Marcel Bonn-Miller, PhD, an adjunct assistant professor of Psychology in Psychiatry at the University of Pennsylvania and the lead author on the study, and his team identified, purchased, and analyzed 84 products from 31 different companies. They found that more than 42% of products had a higher concentration of CBD than indicated (“under-labeled”) and 26% had a lower concentration of CBD than indicated (“over-labeled”). In fact, only 30% of products had a CBD concentration that was within 10% of the amount listed on the product label. Additionally, Δ-9-tetrahydrocannabibolic acid (THC), the psychoactive cannabinoid that produces a “high”, was detected in 21% of samples. According to Dr. Bonn-Miller, “People are using this as medicine for many conditions (anxiety, inflammation, pain, epilepsy). The biggest implication is that many of these patients may not be getting the proper dosage; they’re either not getting enough for it to be effective or they’re getting too much.” While studies have not shown that too much CBD can be harmful, products containing either too little or too much CBD than labeled could confuse the consumer and/or have unintended consequences. Further, the variability across products may make it troublesome for patients to get a reliable effect.